Actovegin® Versus Placebo in Patients With Diabetic Polyneuropathy (AV-007-IM)
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
To assess clinical efficacy and safety of Actovegin in type 2 diabetic patients with
symptomatic diabetic peripheral polyneuropathy after 250 ml i.v. infusions once daily for 20
days followed by oral treatment 600 mg × 3 daily for 140 days.